Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Little Green Pharma Ltd. ( (AU:LGP) ) is now available.
Little Green Pharma has confirmed the dispatch of a supplementary scheme booklet to Cannatrek shareholders, providing additional information on LGP’s proposed acquisition of 100% of Cannatrek via a scheme of arrangement. The materials, available electronically and by post, are intended to help Cannatrek investors assess the deal ahead of the scheme meeting and outline LGP’s post-transaction intentions, risks, and voting procedures.
The scheme remains supported by both boards and an independent expert, with RSM Corporate Australia reiterating that the transaction is fair, reasonable, and in Cannatrek shareholders’ best interests in the absence of a superior proposal. Directors of both companies have stated they will vote all shares they control in favour of the respective resolutions, reinforcing strong internal backing for the deal and signalling continued consolidation in Australia’s medicinal cannabis industry.
The most recent analyst rating on (AU:LGP) stock is a Buy with a A$0.18 price target. To see the full list of analyst forecasts on Little Green Pharma Ltd. stock, see the AU:LGP Stock Forecast page.
More about Little Green Pharma Ltd.
Little Green Pharma Ltd. is an Australia-based medicinal cannabis company focused on cultivating, manufacturing, and supplying cannabis-derived therapies. Listed on the ASX under the ticker LGP, the company is expanding its market presence through strategic acquisitions in the medical cannabis sector, including the proposed purchase of Cannatrek Ltd.
Average Trading Volume: 177,397
Technical Sentiment Signal: Sell
Current Market Cap: A$28.75M
Find detailed analytics on LGP stock on TipRanks’ Stock Analysis page.